Drug Type Small molecule drug |
Synonyms BI 853520, BI-853520, IN 10018 + [2] |
Target |
Mechanism FAK inhibitors(Focal adhesion kinase inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 3 |
First Approval Date- |
RegulationFast Track (US), Breakthrough Therapy (CN) |
Molecular FormulaC28H28F4N6O4 |
InChIKeyULMMVBPTWVRPSI-UHFFFAOYSA-N |
CAS Registry1227948-82-4 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Ovarian Cancer | Phase 3 | CN | 29 Aug 2022 | |
Ovarian Cancer | Phase 3 | HK | 29 Aug 2022 | |
ES-SCLC | Phase 2 | CN | 20 Sep 2023 | |
EGFR positive non-small cell lung cancer | Phase 2 | CN | 13 Jul 2023 | |
Advanced Pancreatic Adenocarcinoma | Phase 2 | CN | 08 Dec 2022 | |
KRAS G12C mutation Solid Tumors | Phase 2 | CN | 12 Oct 2022 | |
Locally Advanced Malignant Solid Neoplasm | Phase 2 | CN | 10 Mar 2022 | |
Solid tumor | Phase 2 | CN | 10 Mar 2022 | |
Ovarian Serous Adenocarcinoma | Phase 2 | CN | 27 Jul 2020 | |
Pancreatic Cancer | Phase 1 | CN | 01 Dec 2022 |
Phase 1/2 | 48 | (KRAS G12C mutant NSCLC) | qpncqqkoxn(hamxtvapuq) = 7 pts (14.6%) had ifebemtinib-related SAEs, and 6 (12.5%) were also considered D-1553 related. hvknzfjppm (anotfjcjos ) View more | Positive | 14 Sep 2024 | ||
(KRAS G12C mutant metastatic CRC) | |||||||
NEWS Manual | Phase 1/2 | 33 | csitgrqsre(perwjjalvc) = bsdsenyycm yryhzdvfgm (lvoeqetzeg ) View more | Positive | 03 Jun 2024 | ||
Phase 1/2 | KRAS G12C mutant Non-small Cell Lung Cancer KRAS G12C mutation | 33 | cvapnnbgfl(lngttsgkyp) = Four subjects (12.1%) had ifebemtinib-related SAEs (diarrhea, enteritis, oedema peripheral and proteinuria) as assessed by investigators, and all SAEs were also considered D-1553 related. Six subjects (18.1%) had ≥ Grade 3 ifebemtinib-related AEs as assessed by investigators, and all were also D-1553 related AEs. The majority of ifebemtinib-related AEs were CTCAE Grade 1 or 2. There was no event leading to study treatment discontinuation. gjclxptuax (iwlzclojxg ) View more | Positive | 24 May 2024 | ||
D-1553 (garsorasib) 600mg bid | |||||||
Phase 1/2 | 26 | IN10018+PLD | cqaiklrdut(jrmxqjkdtg) = zikuevxarm htpctmfdpu (torrxfqfze, 2.1 - 48.4) View more | Positive | 21 Oct 2023 | ||
cqaiklrdut(jrmxqjkdtg) = ubozjzhfea htpctmfdpu (torrxfqfze, 3.8 - 42.8) View more | |||||||
NCT05551507 (NEWS) Manual | Phase 1 | 50 | xfwhgjgdue(cdxlsvomqu) = uxmlcqohdz isdkotnvjt (ntcrdtuzwu ) View more | Positive | 11 Nov 2022 | ||
Phase 1 | 50 | IN10018 100mg QD + PLD 40mg/m2 Q4W | ceejmokbzv(jupmwwbuhv) = olartdimmt wlqwgerlex (fexvycrsjt, 38.7%, 70.2%) View more | Positive | 21 Sep 2022 | ||
ASCO2022 Manual | Phase 1 | 42 | byfzupdzda(laewsvbnpm) = khccgdvlhi wvltsshvcn (defdwcyqte, 37.4 - 74.5) View more | Positive | 02 Jun 2022 | ||
(patients who had at least 6 months of follow up) | byfzupdzda(laewsvbnpm) = fuexsdzpge wvltsshvcn (defdwcyqte, 40.8 - 84.6) View more | ||||||
Phase 1 | 96 | (200 mg QD) | ocwnaujcbm(xtfbofkplr) = rosqiuujve ypjflizgfn (tcforosghz ) View more | Positive | 01 Feb 2019 | ||
cvyjoxgliz(zkzhzmacru) = osqisothcp lxoxbcdcif (udeocpgkpl ) View more | |||||||
Phase 1 | 21 | rblfottcuj(jxgvqlrnxi) = mjpnknouqv kybewogdfn (qkxflweopx ) View more | Positive | 01 Feb 2019 |